Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-06-26
2010-10-12
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S348100, C548S351100, C548S355100
Reexamination Certificate
active
07812047
ABSTRACT:
The present invention relates to compounds of formulawhereinR1, R2, X, Y and Ar are as defined hereinand to their pharmaceutically active salts, with the exclusion of the racemic compound 4-benzyl-4,5-dihydro-1H-imidazole or its tautomer (CAS 131548-83-9). Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1 and are useful for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
REFERENCES:
patent: 2161938 (1939-06-01), Sonn
patent: 2457047 (1948-12-01), Kyrides
patent: 2731471 (1956-01-01), Synerholm et al.
patent: 2744909 (1956-05-01), Speeter
patent: 2744910 (1956-05-01), Speeter
patent: 2778836 (1957-01-01), Morren
patent: 2919274 (1959-12-01), Faust et al.
patent: 3161653 (1964-12-01), Fruhstorfer et al.
patent: 3354175 (1967-11-01), Fruhstorfer et al.
patent: 3377247 (1968-04-01), Elbe
patent: 3586695 (1971-06-01), Wysong et al.
patent: 3622579 (1971-11-01), Stahle et al.
patent: 3660423 (1972-05-01), Wysong et al.
patent: 3758476 (1973-09-01), Rippel et al.
patent: 3818035 (1974-06-01), Binon et al.
patent: 3818094 (1974-06-01), Stahle et al.
patent: 3992403 (1976-11-01), Roebke
patent: 4125620 (1978-11-01), Stahle et al.
patent: 4146647 (1979-03-01), Lafon
patent: 4323570 (1982-04-01), Stenzel et al.
patent: 4665095 (1987-05-01), Winn et al.
patent: 4826861 (1989-05-01), Gerard et al.
patent: 5610174 (1997-03-01), Craig et al.
patent: 5658938 (1997-08-01), Geerts et al.
patent: 2002/0019390 (2002-02-01), Wong et al.
patent: 2003/0181354 (2003-09-01), Abdulrazik
patent: 2003/0236274 (2003-12-01), Tasaka et al.
patent: 2246027 (2000-02-01), None
patent: 0 024 829 (1981-03-01), None
patent: 0 125 410 (1984-11-01), None
patent: 0 166 937 (1986-01-01), None
patent: 0 331 374 (1989-09-01), None
patent: 0 424 059 (1991-04-01), None
patent: 0 857 483 (1998-08-01), None
patent: 0 924 209 (1999-06-01), None
patent: 1 103 243 (2001-05-01), None
patent: 1 413 576 (2004-04-01), None
patent: 323 985 (1966-12-01), None
patent: 6 551 (1968-12-01), None
patent: 877306 (1961-09-01), None
patent: 1016514 (1966-01-01), None
patent: WO 96/22768 (1996-08-01), None
patent: WO 97/12874 (1997-04-01), None
patent: WO 98/12183 (1998-03-01), None
patent: WO 01/30762 (2001-05-01), None
patent: WO 01/81334 (2001-11-01), None
patent: WO 02/22801 (2002-03-01), None
patent: WO 02/40453 (2002-05-01), None
patent: WO 02/076950 (2002-10-01), None
patent: WO 03/092374 (2003-11-01), None
patent: WO 2004/014898 (2004-02-01), None
patent: WO 2005/040166 (2005-05-01), None
patent: WO 2006/119411 (2006-11-01), None
patent: WO 2007/024944 (2007-03-01), None
patent: WO 2007/085556 (2007-08-01), None
patent: WO 2007/090720 (2007-08-01), None
Defacqz, Nathalie et al, “Synthesis of C5-substituted imidazolines,” Tetrahedron Letters (2003), vol. 44, pp. 9111-9114.
Deutch et al., (1999) Neurotransmitters. In Fundamental Neuroscience (2nded.) pp. 193-234, Academic Press.
Wong, et al., (2001) Nat. Rev. Neurosci. 2, pp. 343-351.
Carlsson. et al. (2001) Annu. Rev. Pharmacol. Toxicol. 41, pp. 237-260.
Tuite et al., (2003) Expert Opin. Investig. Drugs 12, pp. 1335-1352.
Castellanos et al., (2002) Nat. Rev. Neurosci. 3, pp. 617-628.
Usdin, E.; Sandler, M.; Editors. Psychopharmacology Series, vol. 1: Trace Amines and the Brain. [Proceedings of a Study Group at the 14th Annual Meeting of the American College of Neuropsychoparmacology, San Juan, Puerto Rico](1976), pp. 1-281.
Lindemann et al., (2005) Trends in Pharmacol. Sci. 26, pp. 274-281.
Branchek et al., (2003) Curr. Opin. Pharmacol. 3, pp. 90-97.
Premont et al. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, pp. 9474-9475.
Mousseau et al., (1995) Prog. Brain Res. 106, pp. 285-291.
McCormack et al. (1986) J. Neurosci. 6, pp. 94-101.
Dyck, L. E. (1989) Life Sci. 44, pp. 1149-1156.
Parker, et al. (1988) J. Pharmacol. Exp. Ther. 245, pp. 199-210.
Lindemann et al. (2005) Genomics 85, pp. 372-385.
Flippin et al., Tetrahedron Letters, vol. 34, pp. 3255-3258 (1993).
Liebigs, Ann. Chem. pp. 2061-2071 (1980).
Huh et al., Tetrahedron, vol. 58, pp. 9925-9932 (2002).
Huh et al., Tetrahedron, vol. 60, pp. 9857-9862 (2004).
Law et al., J. Med. Chem. vol. 41, pp. 2243-2251 (1998).
Debernardis et al., J. Med. Chem. vol. 29, pp. 1413-1417 (1986).
Mohammadpoor-Baltork, Bull. Korean Chem. Soc. vol. 24, p. 1354-1356 (2003).
Abdollahi-Alibeik et al., Bioorg. Med. Chem. Lett. vol. 14, pp. 6079-6082 (2004).
Amemiya, Synth. Commun. vol. 20, pp. 2483-2489 (1990).
Ohta, Chem. Pharm. Bull. vol. 35, pp. 1058-1069 (1987).
Olah, Synlett pp. 647-650 (1992).
Katz et al., Tetrahedron, vol. 45, pp. 1801-1814 (1989).
Wentland et al., J. Med. Chem. vol. 30, pp. 1482-1489 (1987).
Campos et al., Heterocycles, vol. 40, p. 841-849 (1995).
Ohta, Synthesis, pp. 78-81 (1990).
Mancuso et al., J. Org. Chem. vol. 43, pp. 2480-2482 (1978).
Mohammadpoor-Baltork, Synlett, pp. 2803-2805 (2004).
Cahiez et al., Synthesis, pp. 2138-2144 (1999).
Evans et al., Tetrahedron Lett. vol. 39, pp. 2937-2940 (1998).
Nakamura et al., J. Chem. Soc. Perkin Trans. 1, pp. 1061-1066 (2002).
Turner, et al. (1991) J. Org. Chem. vol. 56, pp. 5739-5740.
Zhang et al., J. Med. Chem. 1997, 40, pp. 3014-3024.
Khimiya Geterotsiklicheskikh Soedinenii, 1988, pp. 77-79.
Reimann et al., Arch. Pharm. 1989, vol. 322, pp. 363-367.
Klapars, et al., J. Am. Chem. Soc. 2001, vol. 123, pp. 7727-7729.
Anderson, et al., Tetrahedron, 2002, vol. 58, pp. 8475-8481.
Touzeau et al., J. Med. Chem. 2003, vol. 46, pp. 1962-1979.
Altenbach et al., Synthesis and Structure-Activity Studies onN-[5-(1H-Imidazol-4-y1)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an Imidasole-Containing β1A-Adrenoceptor Agonist, J. Med. Chem. (2004), 47: 3220-3235.
Amemiya et al., Synthesis and β-Adrenergic Activities of 2-and 4-Substituted Imidazoline and Imidazoline Analogues, J. Med. Chem. (1992), 35:750-755.
Bagley et al., Synthesis and β2-Adrenegeric Activities of Imidazole and Imidazolidine Analogues: In Vitro and In Vivo Selectivity, Medicinal Chemistry Research (1994), 4:346-364.
Branchek et al., Trace amine receptors as targets for novel therapeutics: legend, myth and fact, Curr. Opin. Phamacol. (2003), 3:90-97.
Bunzow et al., Amphetamine, 3,4-Methylenedioxymethamphetamine, Lysergic Acid Diethylamide, and Metabolites of the catecholamine Neurotransmitters Are Agonists of a Rat Trace Amine Receptor, Molecular Pharmacology (2001), 60: 1181-1188.
Carroll et al., In Vitro and In Vivo Characterization of Alpha-1A Selective Agonists and Their Utility for Stress Incontinence, Med. Chem. Res. (2004), 13:134-148.
De Bernardis et al., Conformationally Defined Adregernic Agents. 5. Resolution, Absolute Configuration, and Pharmacological Characterization of the Enantiomers of 2-(5,6-Dihydroxy-1,2,3,4-tetrahydro-1-naphthyl)imidazoline: A Potent Agonist at β—Adrenoceptors, J. Med. Chem. (1987), 30:1011-1017.
Faust et al., Antihypertensive Agents: Derivatives of 2-Imidazoline and 1,4,5,6-Tetrahydropyrimidine, J. Org. Chem. (1961), 26: 4044-4047.
Hirashima et al., Three-Dimensional Common-Feature Hypotheses for Octopamine Agonist 2-(Arylimino)imidazolidines, Bioorganic & Medicinal Chemistry (2002), 10:117-123.
Holt, A., Imidazoline binding sites on receptors and enzymes:Emerging targets for novel antidepressant drugs?, Journal of Psychiatry & Neuroscience (2003), 28:409-414.
Jetter et al., Synthesis of 4-Substituted Imidazoles via Palladium-Catalyzed Cross-Coupling Reactions, Synthesis (1998), 829-831.
Law et al., Ben
Galley Guido
Groebke Zbinden Katrin
Norcross Roger
Stalder Henri
Coppins Janet L
Hoffman-La Roche Inc.
Johnston George W.
McKane Joseph K.
Prior Kimberly J.
LandOfFree
4-imidazolines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4-imidazolines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-imidazolines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4160347